40 reports of this reaction
1.9% of all TAZAROTENE reports
#11 most reported adverse reaction
PSORIASIS is the #11 most commonly reported adverse reaction for TAZAROTENE, manufactured by Almirall, LLC. There are 40 FDA adverse event reports linking TAZAROTENE to PSORIASIS. This represents approximately 1.9% of all 2,077 adverse event reports for this drug.
Patients taking TAZAROTENE who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for TAZAROTENE, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for TAZAROTENE:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 40 FDA reports for TAZAROTENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 1.9% of all adverse event reports for TAZAROTENE, making it a notable side effect.
If you experience psoriasis while taking TAZAROTENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.